Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer

M. Manzoni, B. Rovati, M. Ronzoni, F. Loupakis, S. Mariucci, V. Ricci, E. Gattoni, L. Salvatore, C. Tinelli, E. Villa, M. Danova

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: The efficacy of bevacizumab in metastatic colorectal cancer (mCRC) could be related not only to its well-known antiangiogenetic properties but also to a hypothetical effect on the immune system of the host. Methods: We enrolled mCRC patients treated with a bevacizumab-based first-line therapy. Lymphocyte and dendritic cell subsets were evaluated at baseline, 3rd and 6th cycle. The clinical efficacy was estimated as response rate and progression-free survival. Forty healthy subjects were used as reference. Results: Fifty-one patients were enrolled. In comparison with healthy subjects, they showed a decrease of T and B cell compartments. Bevacizumab ameliorated the impairment of lymphocyte subsets, especially for T cells. Responders showed a trend toward an increase of CD3 (p = 0.07) and CD4 (p = 0.05). Among patients with a progression-free survival >1 year, only CD19 (p = 0.033) and CD20 (p = 0.013) showed a significant increase. No baseline impairment and no significant modification of dendritic cells were found. Conclusion: Bevacizumab-based therapy is able to increase B and T cell compartments. The expansion of T lymphocytes could imply an amelioration of dendritic cell-presenting capacity. These effects correlate with a more favourable clinical outcome and could be taken into account in clinical protocols aimed at combining antiangiogenetic- therapy with immunotherapy in mCRC.

Original languageEnglish
Pages (from-to)187-196
Number of pages10
JournalOncology
Volume79
Issue number3-4
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Colorectal Neoplasms
Dendritic Cells
T-Lymphocyte Subsets
T-Lymphocytes
Disease-Free Survival
Healthy Volunteers
B-Lymphocytes
Therapeutics
Clinical Protocols
Immunotherapy
Immune System
Lymphocytes
Bevacizumab

Keywords

  • Advanced colorectal cancer
  • Angiogenesis
  • Dendritic cells
  • Immunophenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. / Manzoni, M.; Rovati, B.; Ronzoni, M.; Loupakis, F.; Mariucci, S.; Ricci, V.; Gattoni, E.; Salvatore, L.; Tinelli, C.; Villa, E.; Danova, M.

In: Oncology, Vol. 79, No. 3-4, 03.2011, p. 187-196.

Research output: Contribution to journalArticle

Manzoni, M, Rovati, B, Ronzoni, M, Loupakis, F, Mariucci, S, Ricci, V, Gattoni, E, Salvatore, L, Tinelli, C, Villa, E & Danova, M 2011, 'Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer', Oncology, vol. 79, no. 3-4, pp. 187-196. https://doi.org/10.1159/000320609
Manzoni, M. ; Rovati, B. ; Ronzoni, M. ; Loupakis, F. ; Mariucci, S. ; Ricci, V. ; Gattoni, E. ; Salvatore, L. ; Tinelli, C. ; Villa, E. ; Danova, M. / Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. In: Oncology. 2011 ; Vol. 79, No. 3-4. pp. 187-196.
@article{4be34414ca5046d789f425d486cb8b28,
title = "Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer",
abstract = "Objective: The efficacy of bevacizumab in metastatic colorectal cancer (mCRC) could be related not only to its well-known antiangiogenetic properties but also to a hypothetical effect on the immune system of the host. Methods: We enrolled mCRC patients treated with a bevacizumab-based first-line therapy. Lymphocyte and dendritic cell subsets were evaluated at baseline, 3rd and 6th cycle. The clinical efficacy was estimated as response rate and progression-free survival. Forty healthy subjects were used as reference. Results: Fifty-one patients were enrolled. In comparison with healthy subjects, they showed a decrease of T and B cell compartments. Bevacizumab ameliorated the impairment of lymphocyte subsets, especially for T cells. Responders showed a trend toward an increase of CD3 (p = 0.07) and CD4 (p = 0.05). Among patients with a progression-free survival >1 year, only CD19 (p = 0.033) and CD20 (p = 0.013) showed a significant increase. No baseline impairment and no significant modification of dendritic cells were found. Conclusion: Bevacizumab-based therapy is able to increase B and T cell compartments. The expansion of T lymphocytes could imply an amelioration of dendritic cell-presenting capacity. These effects correlate with a more favourable clinical outcome and could be taken into account in clinical protocols aimed at combining antiangiogenetic- therapy with immunotherapy in mCRC.",
keywords = "Advanced colorectal cancer, Angiogenesis, Dendritic cells, Immunophenotype",
author = "M. Manzoni and B. Rovati and M. Ronzoni and F. Loupakis and S. Mariucci and V. Ricci and E. Gattoni and L. Salvatore and C. Tinelli and E. Villa and M. Danova",
year = "2011",
month = "3",
doi = "10.1159/000320609",
language = "English",
volume = "79",
pages = "187--196",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3-4",

}

TY - JOUR

T1 - Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer

AU - Manzoni, M.

AU - Rovati, B.

AU - Ronzoni, M.

AU - Loupakis, F.

AU - Mariucci, S.

AU - Ricci, V.

AU - Gattoni, E.

AU - Salvatore, L.

AU - Tinelli, C.

AU - Villa, E.

AU - Danova, M.

PY - 2011/3

Y1 - 2011/3

N2 - Objective: The efficacy of bevacizumab in metastatic colorectal cancer (mCRC) could be related not only to its well-known antiangiogenetic properties but also to a hypothetical effect on the immune system of the host. Methods: We enrolled mCRC patients treated with a bevacizumab-based first-line therapy. Lymphocyte and dendritic cell subsets were evaluated at baseline, 3rd and 6th cycle. The clinical efficacy was estimated as response rate and progression-free survival. Forty healthy subjects were used as reference. Results: Fifty-one patients were enrolled. In comparison with healthy subjects, they showed a decrease of T and B cell compartments. Bevacizumab ameliorated the impairment of lymphocyte subsets, especially for T cells. Responders showed a trend toward an increase of CD3 (p = 0.07) and CD4 (p = 0.05). Among patients with a progression-free survival >1 year, only CD19 (p = 0.033) and CD20 (p = 0.013) showed a significant increase. No baseline impairment and no significant modification of dendritic cells were found. Conclusion: Bevacizumab-based therapy is able to increase B and T cell compartments. The expansion of T lymphocytes could imply an amelioration of dendritic cell-presenting capacity. These effects correlate with a more favourable clinical outcome and could be taken into account in clinical protocols aimed at combining antiangiogenetic- therapy with immunotherapy in mCRC.

AB - Objective: The efficacy of bevacizumab in metastatic colorectal cancer (mCRC) could be related not only to its well-known antiangiogenetic properties but also to a hypothetical effect on the immune system of the host. Methods: We enrolled mCRC patients treated with a bevacizumab-based first-line therapy. Lymphocyte and dendritic cell subsets were evaluated at baseline, 3rd and 6th cycle. The clinical efficacy was estimated as response rate and progression-free survival. Forty healthy subjects were used as reference. Results: Fifty-one patients were enrolled. In comparison with healthy subjects, they showed a decrease of T and B cell compartments. Bevacizumab ameliorated the impairment of lymphocyte subsets, especially for T cells. Responders showed a trend toward an increase of CD3 (p = 0.07) and CD4 (p = 0.05). Among patients with a progression-free survival >1 year, only CD19 (p = 0.033) and CD20 (p = 0.013) showed a significant increase. No baseline impairment and no significant modification of dendritic cells were found. Conclusion: Bevacizumab-based therapy is able to increase B and T cell compartments. The expansion of T lymphocytes could imply an amelioration of dendritic cell-presenting capacity. These effects correlate with a more favourable clinical outcome and could be taken into account in clinical protocols aimed at combining antiangiogenetic- therapy with immunotherapy in mCRC.

KW - Advanced colorectal cancer

KW - Angiogenesis

KW - Dendritic cells

KW - Immunophenotype

UR - http://www.scopus.com/inward/record.url?scp=79952055852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952055852&partnerID=8YFLogxK

U2 - 10.1159/000320609

DO - 10.1159/000320609

M3 - Article

VL - 79

SP - 187

EP - 196

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -